T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide

被引:237
作者
Tynan, FE
Burrows, SR
Buckle, AM
Clements, CS
Borg, NA
Miles, JJ
Beddoe, T
Whisstock, JC
Wilce, MC
Silins, SL
Burrows, JM
Kjer-Nielsen, L
Kostenko, L
Purcell, AW
McCluskey, J
Rossjohn, J [1 ]
机构
[1] Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Prot Crystallog Unit, Clayton, Vic 3800, Australia
[2] Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia
[3] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
[4] Univ Melbourne, Dept Biochem, Parkville, Vic 3010, Australia
基金
英国惠康基金;
关键词
D O I
10.1038/ni1257
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Unusually long major histocompatibility complex (MHC) class I-restricted epitopes are important in immunity, but their 'bulged' conformation represents a potential obstacle to ab T cell receptor (TCR)-MHC class I docking. To elucidate how such recognition is achieved while still preserving MHC restriction, we have determined here the structure of a TCR in complex with HLA-B*3508 presenting a peptide 13 amino acids in length. This complex was atypical of TCR-peptide-MHC class I interactions, being dominated at the interface by peptide-mediated interactions. The TCR assumed two distinct orientations, swiveling on top of the centrally bulged, rigid peptide such that only limited contacts were made with MHC class I. Although the TCR-peptide recognition resembled an antibody-antigen interaction, the TCR-MHC class I contacts defined a minimal 'generic footprint' of MHC-restriction. Thus our findings simultaneously demonstrate the considerable adaptability of the TCR and the 'shape' of MHC restriction.
引用
收藏
页码:1114 / 1122
页数:9
相关论文
共 66 条
[1]   Structure of a γδ T cell receptor in complex with the nonclassical MHC T22 [J].
Adams, EJ ;
Chien, YH ;
Garcia, KC .
SCIENCE, 2005, 308 (5719) :227-231
[2]   DIFFERENTIAL TRANSPORT REQUIREMENTS OF HLA AND H-2 CLASS-I GLYCOPROTEINS [J].
ALEXANDER, J ;
PAYNE, JA ;
MURRAY, R ;
FRELINGER, JA ;
CRESSWELL, P .
IMMUNOGENETICS, 1989, 29 (06) :380-388
[3]   Identification of a crucial energetic footprint on the al helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides functional interactions for recognition by tax peptide/HLA-A2-specifrc T cell receptors [J].
Baker, BM ;
Turner, RV ;
Gagnon, SJ ;
Wiley, DC ;
Biddison, WE .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (05) :551-562
[4]   A SYSTEMATIC MUTATIONAL ANALYSIS OF HORMONE-BINDING DETERMINANTS IN THE HUMAN GROWTH-HORMONE RECEPTOR [J].
BASS, SH ;
MULKERRIN, MG ;
WELLS, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4498-4502
[5]   Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition [J].
Baxter, TK ;
Gagnon, SJ ;
Davis-Harrison, RL ;
Beck, JC ;
Binz, AK ;
Turner, RV ;
Biddison, WE ;
Baker, BM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (28) :29175-29184
[6]   The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition [J].
Borg, NA ;
Ely, LK ;
Beddoe, T ;
Macdonald, WA ;
Reid, HH ;
Clements, CS ;
Purcell, AW ;
Kjer-Nielsen, L ;
Miles, JJ ;
Burrows, SR ;
McCluskey, J ;
Rossjohn, J .
NATURE IMMUNOLOGY, 2005, 6 (02) :171-180
[7]   Conserved CDR3 regions in T-cell receptor (TCR) CD8+ T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-Cell leukemia virus type 1:: Relationship of T-cell fine specificity and major histocompatibility complex/peptide/TCR crystal structure [J].
Bourcier, KD ;
Lim, DG ;
Ding, YH ;
Smith, KJ ;
Wucherpfennig, K ;
Hafler, DA .
JOURNAL OF VIROLOGY, 2001, 75 (20) :9836-9843
[8]   T-CELL RECEPTOR REPERTOIRE FOR A VIRAL EPITOPE IN HUMANS IS DIVERSIFIED BY TOLERANCE TO A BACKGROUND MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN [J].
BURROWS, SR ;
SILINS, SL ;
MOSS, DJ ;
KHANNA, R ;
MISKO, IS ;
ARGAET, VP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) :1703-1715
[9]  
CHEN Y, 1994, J IMMUNOL, V152, P2874
[10]  
CLAVERIE JM, 1986, ANN INST PASTEUR IMM, VD137, P425